EUCAST-AFST Available breakpoints 2012

Similar documents
Update zu EUCAST 2012 Cornelia Lass-Flörl

Antifungal susceptibility testing: Which method and when?

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013

Antifungal Pharmacotherapy

Resistance epidemiology

Voriconazole Rationale for the EUCAST clinical breakpoints, version March 2010

(and breakpoint table, MIC and. by author. ESCMID Online Lecture Library. conventions) ECCMID 2011, Milan

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Table 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.

Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009

About the Editor Gerri S. Hall, Ph.D.

Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside

Antifungal Susceptibility Testing

An Update in the Management of Candidiasis

on December 9, 2018 by guest

Antifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul

Antifungal Drug Resistance: a Cause for Concern?

Echinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden

Effect of reduced oxygen on the antifungal susceptibility of clinically relevant

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

AAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac

Oslo meeting May 21st 2014

Antifungal therapy in children. Adilia Warris MD PhD FRCPCH Clinical Reader Pediatric Infectious Diseases Specialist

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences

Received 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011

The Antifungal Pipeline Maertens Johan, MD, PhD

Voriconazole. Voriconazole VRCZ ITCZ

ESCMID Online Lecture Library. by author

Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units

Received 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009

Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent?

Candidemia: New Sentinel Surveillance in the 7-County Metro

Fungal Infection Pre-Infusion Data

on November 3, 2018 by guest

The Evolving Role of Antifungal Susceptibility Testing. Gregory A. Eschenauer and Peggy L. Carver

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS

SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY

Clinical relevance of resistance in Aspergillus. David W. Denning University Hospital of South Manchester [Wythenshawe Hospital]

Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical

National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing

9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?

In vitro cross-resistance between azoles in Aspergillus fumigatus: a reason for concern in the clinic?

Received 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008

Clinical Considerations in the Management of Systemic Fungal Infections. Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California

Received 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010

Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study

Coleophoma empetri FR901379, Fig. 1, ,,, 1,3- -D-glucan. . C. albicans A. fumigatus. Dixon plot C. albicans A. fumigatus 1,3- -D-glucan

Received 6 October 2010/Returned for modification 26 December 2010/Accepted 7 January 2011

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017

Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing

Review. Ana Espinel-Ingroff

Antifungal resistance mechanisms in pathogenic fungi

Research Article In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance

SCY-078 ECMM Symposium Cologne, Germany October 2017

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003

Fungal Infection Post-Infusion Data

The incidence of invasive fungal infections

ESCMID Online Lecture Library. by author

on March 29, 2019 by guest

C. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS

Antifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study.

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR

ESCMID Online Lecture Library. by author

Abstract. Introduction. Editor: E. Roilides

Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing

Received 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006

Synthesis and Antifungal Activity of Perylene Bisimide Derivatives

Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies

Use of Antifungal Drugs in the Year 2006"

Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients

Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus

1* 1. Vijaya S. Rajmane, Shivaji T. Mohite

Isolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.

Antifungal Therapy in Leukemia Patients

A rare case of breakthrough fungal pericarditis due to fluconazole-resistant Candida auris in a patient with chronic liver disease

Antifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?

Echinocandin Antifungal Drugs in Fungal Infections

Reducing the antifungal drugs consumption in the ICU

Invasive Fungal Infections in Solid Organ Transplant Recipients

Department of Animal Production, Faculty of Agriculture, Baghdad University, Baghdad, Iraq

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?

New Options for Prevention & Treatment of Invasive Fungal Infections

Received 5 August 2004/Accepted 26 September 2004

Antifungals and current treatment guidelines in pediatrics and neonatology

Recent advances in the treatment of IFIs Newer antifungals: what s in the pipeline

Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures

Treatment of rare and emerging fungal infections. EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen

Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species

Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients

14/05/ <500/mm 3

Update on Candida Infection Nov. 2010

Candida auris - an update on a globally emerging pathogen

Received 12 May 2010/Returned for modification 24 June 2010/Accepted 6 July 2010

Research what you see: Antimicrobial resistance and pathogenesis

Rapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia

Transcription:

EUCAST-AFST Available breakpoints th NSMM meeting Göteborg, Sweden October th

EUCAST-AFST documents Reference Methods Yeast E.DEF. () TN- E.DEF. (CMI epub July) E.DEF. () TN- E.DEF. () Breakpoints Compound Candida Conidia forming moulds E.DEF. () TN-E.DEF. () Aspergillus Rationale Doc Techn. Note CMI Rationale Doc Techn. Note CMI Amphotericin epub July Anidulafungin Fluconazole - - Itraconazole epub July Posaconazole epub July Voriconazole In prep.

EUCAST BP establishing procedure MIC distributions Per species Several data sets Epidemiological Cut Off Value (ECOFF) MIC-clinical outcome relationships Per species For wild type and non-wild type isolates PK/PD defining the important parameter and ratio (AUC/MIC, Peak/MIC, Time/MIC) are non wild type covered during standard dosing? BP never higher than ECOFF unless supported by data

EUCAST Candida BPs Breakpoints (BPs): S: X / R: >Y Antifungal agent C. albicans C. glabrata C. krusei MIC breakpoint (mg/l) C. parapsilosis C. tropicalis C. guilliermondii Non-species related breakpoints Ampho. B / / / / / IE IE Anidulafungin./../../. -*./. IE IE Fluconazole / IE* - / / IE / Posaconazole./. IE IE./../. IE IE Voriconazole./. IE IE./../. IE IE denotes the MICs for this species is generally higher than those for C. albicans denotes that voriconazole should be reserved for situations where fluconazole is not appropriate - denotes the organism is regarded a poor target for the antimicrobial agent Current revision proposals *For C. glabrata and fluconazole it is proposed to categorise mg/l as I and > mg/l as R *For C. parapsilosis and anidulafungin it is proposed to categorise mg/l as I and > mg/l as R Breakpoints under development: Micafungin and Candida

CLSI versus EUCAST Breakpoints (BPs): S: X; R: >Y CLSI M-S CLSI revised (M-S) EUCAST AMB ; > ANF.; >. (alb, krus, trop).; >. (glab) ; > (para, guillier) CSF - MFG.; >. (alb, krus, trop).; >. (glab) ; > (para, guillier) Fluco ; > ; > (alb, para, trop) SDD ; > (glab) (krus poor target) Vori ; >.; >. (alb, para, trop).; > Revised BPs (krus).; >. (alb).; >. (glab, krus, trop) (para poor target, guillier IE) www.eucast.org; Pfaller Drug Resist Updat. EUCAST-AFST: & MC Arendrup (Chair), WW Hope (Secretary), M Cuenca-Estrella & C Lass-Flörl - ; > (alb, trop, para) (glab IE) (krus poor target).; >. (alb, trop, para) (glab/krus IE) (glab IE) Itra.; >..; >. - Posa - -.; >. (alb, trop, para) (glab/krus IE)

A N I. CLSI echinocandin MICs M-S BP C. albicans C. glabrata C. krusei C. parapsilosis C. tropicalis.. C. albicans (S) C. albicans (R)... C. glabrata (S) C. glabrata (R)... C. krusei (S) C. krusei (R)... C. parapsilosis (S)... C. tropicalis (S) C. tropicalis (R) C A S C. albicans (S) C. albicans (R) C. glabrata (S) C. glabrata (R) C. krusei (S) C. krusei (R) C. parapsilosis (S) C. tropicalis (S) C. tropicalis (R)............... M I C A... C. albicans (S) C. albicans (R) Arendrup et al AAC, CLSI M-S... C. glabrata (S) C. glabrata (R)... C. krusei (S) C. krusei (R)... C. parapsilosis (S)... C. tropicalis (S) C. tropicalis (R)

CLSI echinocandin testing revised BP A N I C. albicans C. glabrata C. krusei C. parapsilosis C. tropicalis C. albicans (S) C. albicans (R) C. glabrata (S) C. glabrata (R) C. krusei (S) C. krusei (R) C. parapsilosis (S) C. tropicalis (S) C. tropicalis (R)............... C A S C. albicans (S) C. albicans (R) C. glabrata (S) C. glabrata (R) C. krusei (S) C. krusei (R) C. parapsilosis (S) C. tropicalis (S) C. tropicalis (R)............... M I C A... C. albicans (S) C. albicans (R) Arendrup AAC, Pfaller Drug Res Updates, M-S... C. glabrata (S) C. glabrata (R)... C. krusei (S) C. krusei (R)... C. parapsilosis (S)... C. tropicalis (S) C. tropicalis (R)

EUCAST & CLSI Anidulafungin MICs Candida sp......... >= ECOFF BP albicans EUCAST * *.. albicans CLSI.. glabrata EUCAST * *.. glabrata CLSI.. krusei EUCAST * *.. krusei CLSI.. parapsilosis EUCAST - parapsilosis CLSI tropicalis EUCAST * *.. tropicalis CLSI.. www.eucast.org and www.clsi.org

Etest: Caspofungin and CLSI BP % % C. albicans() Etest % % C. glabrata () Etest % -% -% -% CLSI () % % -% -% -% CLSI () MIC (mg/l) Titel % % % % % % -% -% -% -% -% C. tropicalis () Etest CLSI () % % % % -% -% -% C. krusei () Etest CLSI () Arendrup & Pfaller AAC Titel Titel

EUCAST Aspergillus BPs BPs indicated as S x / R >y AF compound Aspergillus flavus fumigatus nidulans niger terreus Amphotericin IE* / Note / Poor Target Itraconazole / / / IE* / Posaconazole IE*./.** IE* IE* Note Voriconazole Note / Note Note Note * MICs are higher than for A. fumigatus ** provided sufficient levels can be achieved Note: the MICs are similar to A. fumigatus but insufficient clinical data for BP setting www.eucast.org

www.eucast.org Website update: the AFST tab

May thanks for your attention Steering Committee MC Arendrup, Chair (Denmark) W Hope, Secretary (UK) C Lass-Flörl(Austria) M Cuenca-Estrella (Spain) General committee S Arikan-Akdagli(Turkey) F Barchiesi(Italy) J Bille(Switzerland) E Chryssanthou(Sweden) P Gaustad(Norway) A Groll(Germany) P Haml(Czech Republic) H Järv(Estonia) K Lagrou(Belgium) O Lortholary(France) N Klimko(Russia) T Matos (Slovenia) C Moore (UK) A Velegraki(Greece) P Verweij(The Netherlands)